Image

Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial

Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial

Recruiting
10-16 years
All
Phase 1/2

Powered by AI

Overview

Background

Children with attention deficit hyperactivity disorder (ADHD) often have cognitive problems. It may be hard for them to control their behaviors, concentrate for long periods, or make decisions. This can affect their education, friendships, and daily life. Virtual reality-based games may help improve cognitive skills in children with ADHD. It may also help change how the brain functions.

Objective

To see if virtual reality-based games help improve thinking skills and brain function in children with ADHD.

Eligibility

Children aged 10 to 16 years with ADHD.

Design

We will first do a pilot study, meaning that everyone will receive the games. If this is successful, we will then conduct a randomized controlled trial, meaning that some participants will be randomly assigned to the full version of the games and some will be randomly assigned to a limited version. Participants will be screened. Their physical and mental health, medical and family history, and intellectual and emotional development will be evaluated. They will have tests of their mood, memory, attention, thinking, and behavior. Blood or saliva may be collected. Participants may have an MRI scan of the brain.

Participants will receive a set of virtual reality games. The set includes 4 different games all played using a virtual reality headset. The participant will play the games for 20 minutes 5 days a week for 4 weeks.

The parent or caregiver will start each game using an iPad. Each of the games is designed to help the participant practice specific cognitive skills. These include inhibition control, processing speed, temporal information processing, and working memory.

Participants will have interviews each week. They will answer questions about motion sickness, eye strain, headache, and any other side effects, as well as number of game sessions played.

Blood or saliva tests and the MRI may be repeated after the last game session. For the pilot, participants will have a final interview at the study end. For the full trial, a 1-month follow-up visit will be done by telehealth.

Description

Study Description: This study will be a randomized double-blind placebo-controlled trial examining the efficacy of a novel virtual reality (VR) adaptive cognitive training intervention for youth with ADHD in improving symptoms of inattention relative to a non-adaptive training control intervention. Prior to the main randomized trial, a proof-of concept open-label pilot study will assess the safety, tolerability, usability, feasibility, credibility and treatment expectancy of the intervention. It will also provide an initial assessment of the efficacy on the intervention in improving inattention symptoms and neuropsychological performance.

Objectives

Primary Objective: Examine the efficacy of the Floreo VR intervention in improving symptoms of inattention in children/adolescents with ADHD.

Secondary Objectives: Examine the efficacy of the VR intervention in improving neuropsychological performance in five cognitive domains pertinent to ADHD.

Pilot Study Objective: Assess the safety, tolerability, usability, feasibility, credibility and treatment expectancy of the VR intervention. Provide an initial open-label assessment of the efficacy of the intervention.

Endpoints

Primary Endpoint: The primary endpoint of the main trial is to investigate whether the intervention decreases symptoms of inattention as assessed using the ADHD Rating Scale-5 for Children and Adolescents (ADHD-RS-5).

A secondary aim of the main study is to investigate whether the intervention brings about improvements in performance on five neuropsychological performance indices. These are parameter A on the Rapid Visual Information Processing task (sustained attention), stop signal reaction time on the Stop Signal task (inhibitory control), visuospatial working memory as determined using number of correct responses on the Dot Matrix task, discounting steepness (parameter k) on the Delay Discounting task, a composite measure of temporal deviation on a Temporal Reproduction task, and the number of correct responses on the NIH Toolbox Pattern Comparison Processing Speed Test. Pilot interventions Endpoints: Responses to structured interview items on safety, tolerability, usability, credibility and treatment expectancy of the intervention. Reports of adverse events will be used to assess safety. Feasibility will be assessed using participation and compliance rates. Usability will also be assessed using a System Usability Scale. Open-label assessments of efficacy will also be performed, using the ADHD-RS-5 inattention subscale. Secondary endpoints for the pilot study are the same as for the main study.

Eligibility

  • INCLUSION CRITERIA:
        In order to be eligible to participate, an individual must meet all of the following
        criteria:
          1. Children must provide informed assent and parents must provide informed consent to
             participate in the study.
          2. Any gender identity, sex assigned at birth or race/ethnicity.
          3. Aged between 10 and 16 years of age, including all months leading up to age 17.
          4. Meets diagnosis for ADHD, predominately inattentive or combined presentations, or a
             specified presentation of having prominent symptoms of inattention that are impairing
             in two or more settings (but not numerous enough to meet a diagnosis of inattentive or
             combined presentation).
          5. Stated willingness to comply with all study procedures and lifestyle considerations
             and availability for the duration of the study.
          6. If treated for ADHD with psychostimulants, willing to withdraw medication three days
             prior to baseline assessments and to stay off medication until completion of the
             post-intervention assessment. Not receiving any other psychotropic medication for at
             least 30 days prior to baseline assessment.
        EXCLUSION CRITERIA:
        An individual who meets any of the following criteria will be excluded from participation
        in this study:
          1. Cognitively not capable of performing study procedures. Indications of a lack of
             cognitive capacity could include a known IQ under 70, or a history from the screening
             interview that implies global intellectual disabilities (e.g., placement in a school
             for children with intellectual disability etc.)
          2. History of severe migraines, vertigo, epilepsy (with the exception of febrile
             seizures), or serious balance disorders.
          3. Impairments in uncorrected visual acuity that would interfere with engagement with the
             VR training.
          4. Known to be pregnant.
          5. Psychotic disorders (including schizophrenia, psychosis not otherwise specified),
             current substance dependence. Other psychiatric disorders elicited on the interview
             are not considered exclusionary provided that ADHD is considered to be one of the
             dominant sources of impairment for the child.
          6. Considered a suicide risk as determined during the clinical interview at baseline.
          7. Any other medical or psychiatric condition that in the opinion of the PI may confound
             study data/assessments (e.g., limitations in mobility that would render the VR headset
             unusable).
          8. Recent (within three months) treatment with other cognitive training interventions
             (e.g., Cogmed) for ADHD.
          9. The VR equipment produces excessive discomfort to the child in the opinion of the PI
             (e.g., including participants with small interpupillary distances (IPD) that are only
             able to see blurry
        images on the VR headset, or children showing signs of undue neck and upper body strain or
        fatigue while trying the headset).

Study details
    Attention Deficit Hyperactivity Disorder

NCT05608434

National Human Genome Research Institute (NHGRI)

23 March 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.